Skip to Main content Skip to Navigation
Journal articles

COVID-19 and Fungal Infections: A Double Debacle

Abstract : Fungal infections remain hardly treatable because of unstandardized diagnostic tests, limited antifungal armamentarium, and more specifically, potential toxic interactions between antifungals and immunosuppressants used during anti-inflammatory therapies, such as those set up in critically ill COVID-19 patients. Taking into account pre-existing difficulties in treating vulnerable COVID-19 patients, any co-occurrence of infectious diseases like fungal infections constitutes a double debacle for patients, healthcare experts, and the public economy. Since the first appearance of SARS-CoV-2, a significant rise in threatening fungal co-infections in COVID-19 patients has been testified in the scientific literature. Better management of fungal infections in COVID-19 patients is, therefore, a priority and requires highlighting common risk factors, relationships with immunosuppression, as well as challenges in fungal diagnosis and treatment. The present minireview attempts to highlight these aspects in the three most identified causative agents of fungal co-infections in COVID-19 patients: Aspergillus, Candida, and Mucorales species.
Document type :
Journal articles
Complete list of metadata
Contributor : Valérie Pecqueret Connect in order to contact the contributor
Submitted on : Monday, August 29, 2022 - 10:19:18 AM
Last modification on : Saturday, September 10, 2022 - 3:52:15 AM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document



Sara Mina, Hajar Yaakoub, Cédric Annweiler, Vincent Dubée, Nicolas Papon. COVID-19 and Fungal Infections: A Double Debacle. Microbes and Infection, Elsevier, 2022, pp.105039. ⟨10.1016/j.micinf.2022.105039⟩. ⟨inserm-03762881⟩



Record views